Home › Funds › Redmile Group, LLC › ALXO

Redmile Group, LLC position in ALXO

ALX ONCOLOGY HLDGS INC · Health Care

Redmile Group, LLC reported holding 7,392,504 shares of ALXO (ALX ONCOLOGY HLDGS INC) in its Q2 2026 13F filing — a position valued at US$15.3M, representing 1.03% of its reported portfolio and ranking #21 among its reported holdings. Redmile Group, LLC has disclosed ALXO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)7.39M sh
Reported value held$15.30M
Portfolio Weight1.03%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Redmile Group, LLC's ALXO position evolved

Redmile Group, LLC first disclosed a stake in ALXO in Q3 2023 at 1,283,289 shares (US$6.2M). The position peaked in Q4 2023 at 3,659,264 shares, worth US$54.5M. Across 12 filings, Redmile Group, LLC increased the stake 3 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 7,392,504 shares valued at US$15.3M — a reduction of -571,684 shares quarter over quarter.. Notable position changes include a 185% increase in Q4 2023 (shares fell 25% over the following quarter), a 144% increase in Q1 2026 (shares rose 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.28M $6.16M New
Q4 2023 3.66M $54.49M Add
Q1 2024 4.33M $48.24M Add
Q2 2024 4.04M $24.34M Reduce
Q3 2024 3.84M $6.98M Reduce
Q4 2024 3.69M $6.16M Reduce
Q1 2025 3.64M $2.27M Reduce
Q2 2025 3.39M $1.41M Reduce
Q3 2025 3.33M $6.10M Reduce
Q4 2025 3.26M $3.69M Reduce
Q1 2026 7.96M $15.97M Add
Q2 2026 7.39M $15.30M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ALXO and 13F data

ALXO (ALX ONCOLOGY HLDGS INC) is a Health Care company. 35 other funds we track also report a position in ALXO — the largest reported positions include venBio Partners LLC (US$26.7M), SILVERARC CAPITAL MANAGEMENT, LLC (US$11.9M), TCG Crossover Management, LLC (US$11.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALXO

All ALXO fund holders →

FAQ

How long has Redmile Group, LLC held ALXO?

Redmile Group, LLC has disclosed ALXO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Redmile Group, LLC's current position in ALXO?

As of Q2 2026, Redmile Group, LLC holds 7.39M shares of ALXO (ALX ONCOLOGY HLDGS INC), valued at $15.30M, representing 1.03% of its reported portfolio and ranking #21.

Has Redmile Group, LLC been buying or selling ALXO?

In the latest 13F filing (Q2 2026), Redmile Group, LLC reduced its position in ALXO. The position peaked in Q4 2023 at 3.66M shares.

Which other funds hold ALXO?

Other major institutional holders of ALXO include venBio Partners LLC, SILVERARC CAPITAL MANAGEMENT, LLC, TCG Crossover Management, LLC, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.